Human Papillomavirus Infection as a Prognostic Factor in Oropharyngeal Squamous Cell Carcinomas Treated in a Prospective Phase II Clinical TrialJO, Solomon; JUHASZ, Agnes; PAZ, Benjamin et al.Anticancer research. 2009, Vol 29, Num 5, pp 1467-1474, issn 0250-7005, 8 p.Article

A phase I trial of ⁹⁰Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancerWONG, Jeffrey Y. C; SHIBATA, Stephen; YAZAKI, Paul J et al.Clinical cancer research. 2003, Vol 9, Num 16, pp 5842-5852, issn 1078-0432, 11 p., 1Article

Postoperative Adjuvant Chemotherapy Use in Patients With Stage II/III Rectal Cancer Treated With Neoadjuvant Therapy: A National Comprehensive Cancer Network AnalysisKHRIZMAN, Polina; NILAND, Joyce C; SCHRAG, Deborah et al.Journal of clinical oncology. 2013, Vol 31, Num 1, pp 30-38, issn 0732-183X, 9 p.Article

Adjuvant Chemotherapy Improves Survival in Patients With American Joint Committee on Cancer Stage II Colon CancerMCKENZIE, Shaun; NELSON, Rebecca; MAILEY, Brian et al.Cancer. 2011, Vol 117, Num 24, pp 5493-5499, issn 0008-543X, 7 p.Article

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium StudyCHAO, Joseph; SYNOLD, Timothy W; BELANI, Chandra P et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 3, pp 835-843, issn 0344-5704, 9 p.Article

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction : A Study by the National Cancer Institute Organ Dysfunction Working GroupGIBBONS, Joseph; EGORIN, Merrill J; PAVLICK, Anna et al.Journal of clinical oncology. 2008, Vol 26, Num 4, pp 570-576, issn 0732-183X, 7 p.Article

Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium TrialYUN YEN; CHOW, Warren; LONGMATE, Jeff et al.Cancer chemotherapy and pharmacology. 2002, Vol 50, Num 5, pp 353-359, issn 0344-5704, 7 p.Article

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyLEAL, Ticiana B; REMICK, Scot C; MIER, James et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 6, pp 1439-1447, issn 0344-5704, 9 p.Article

Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancerMORGAN, Robert J; SYNOLD, Timothy W; TETEF, Merry et al.Cancer chemotherapy and pharmacology. 2004, Vol 54, Num 4, pp 283-289, issn 0344-5704, 7 p.Article

Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapySOMLO, George; FRANKEL, Paul; TWARDOWSKI, Przemyslaw et al.Journal of clinical oncology. 2004, Vol 22, Num 10, pp 1839-1848, issn 0732-183X, 10 p.Article

Predicting Acute and Persistent Neuropathy Associated With OxaliplatinALEJANDRO, Linh M; BEHRENDT, Carolyn E; KIM CHEN et al.American journal of clinical oncology. 2013, Vol 36, Num 4, pp 331-337, issn 0277-3732, 7 p.Article

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group StudyRAMALINGAM, Suresh S; KUMMAR, Shivaani; IVY, S. Percy et al.Journal of clinical oncology. 2010, Vol 28, Num 29, pp 4507-4512, issn 0732-183X, 6 p.Article

Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumorsMORGAN, Robert J; SYNOLD, Timothy; SOMLO, George et al.Cancer chemotherapy and pharmacology. 2010, Vol 66, Num 5, pp 927-933, issn 0344-5704, 7 p.Article

Phase I trial of intraperitoneal gemcitabine in thetreatment of advanced malignancies primarily confined to the peritoneal cavityMORGAN, Robert J; SYNOLD, Timothyw; YUNYEN et al.Clinical cancer research. 2007, Vol 13, Num 4, pp 1232-1237, issn 1078-0432, 6 p.Article

Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: Dose-limiting toxicity and pharmacokineticsMORGAN, Robert J; DOROSHOW, James H; YUN YEN et al.Clinical cancer research. 2003, Vol 9, Num 16, pp 5896-5901, issn 1078-0432, 6 p., 1Article

A Phase I Study of a Combination of Yttrium-90― Labeled Anti ― Carcinoembryonic Antigen (CEA) Antibody and Gemcitabine in Patients with CEA-Producing Advanced MalignanciesSHIBATA, Stephen; RAUBITSCHEK, Andrew; LEONG, Lucille et al.Clinical cancer research (Print). 2009, Vol 15, Num 8, pp 2935-2941, issn 1078-0432, 7 p.Article

A phase I study of oxaliplatin in combination with gemcitabine : correlation of clinical outcome with gene expressionSHIBATA, Stephen; CHOW, Warren; YUN YEN et al.Cancer chemotherapy and pharmacology. 2007, Vol 59, Num 4, pp 549-557, issn 0344-5704, 9 p.Article

Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignanciesCHOW, Warren A; SYNOLD, Timothy W; MORGAN, Robert J et al.Cancer chemotherapy and pharmacology. 2004, Vol 54, Num 3, pp 241-248, issn 0344-5704, 8 p.Article

Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: Lack of neuroprotective effect of amifostineOPENSHAW, Harry; BEAMON, Karen; SOMLO, George et al.Clinical cancer research. 2004, Vol 10, Num 2, pp 461-467, issn 1078-0432, 7 p.Article

Continuous infusion prochlorperazine : pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapyMORGAN, Robert J; SYNOLD, Timothy; CHOW, Warren et al.Cancer chemotherapy and pharmacology. 2001, Vol 47, Num 4, pp 327-332, issn 0344-5704Article

Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignanciesTETEF, Merry L; SYNOLD, Timothy W; GROSHEN, Susan et al.Clinical cancer research. 2001, Vol 7, Num 6, pp 1569-1576, issn 1078-0432Article

A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumorsIQBAL, Syma; LENZ, Heinz-Josef; GANDARA, David R et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 1, pp 85-91, issn 0344-5704, 7 p.Article

Impact of intraoperative radiation on postoperative and disease-specific outcome after pancreatoduodenectomy for adenocarcinoma: A propensity score analysisSCHWARZ, Roderich E; SMITH, David D; KENY, Hemant et al.American journal of clinical oncology. 2003, Vol 26, Num 1, pp 16-21, issn 0277-3732, 6 p.Article

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium StudySHIBATA, Stephen I; DOROSHOW, James H; MARGOLIN, Kim A et al.Cancer chemotherapy and pharmacology. 2009, Vol 64, Num 6, pp 1149-1155, issn 0344-5704, 7 p.Article

A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine ARASCHKO, James W; SYNOLD, Timothy W; TETEF, Merry L et al.Cancer chemotherapy and pharmacology. 2000, Vol 46, Num 5, pp 403-410, issn 0344-5704Article